Leader in the development,
of pharmacogenetics tests
for cancer precision medicine.
Diatech Pharmacogenetics, in order to compete better on the molecular medicine market, has created a network of the following companies:
Diatech Labline s.r.l. a socio unico established in 2011, focused on the distribution of products and reagents for molecular biology and cellular biology labs.
BiMind s.r.l. established in 2009, is a software house which has developed “iGenetics”, an innovative software package for the electronic oncological and anatomopathology clinical record.
Quality in our products
Competition in a high technology market requires strict quality control of all commercial and scientific parameters.
Diatech Pharmacogenetics has reached this goal by achieving:
Diatech Pharmacogenetics is the Italian leader in the development, production and commercialisation of pharmacogenetics tests for cancer precision medicine.
Founded in 1996, Diatech Pharmacogenetics has sustained constant organic growth over the years and now owns more than 70% of the Italian molecular diagnostic market and it is rapidly growing worldwide; to date, more than 20.000 diagnostic tests have been performed using its solutions and every year Diatech Pharmacogenetics reinvests 20% of it revenues in R&D.
Diatech Pharmacogenetics is able to take pharmacogenetics tests from idea to market on a variety of platforms, from real-time PCR to barcoded microarrays, mass-spectrometry and next generation sequencing, supplying all reagents, instruments, materials and support necessary. Its complete solutions guide diagnostic operators from sample extraction, quality control, molecular assay to bioinformatic analysis and report.
The latest products launched include a liquid biopsy cfDNA extraction kit, a real-time PCR system with all reagent provided in a dry and stable format, micro-satellite instability assays and an end-to-end NGS solution that works on both Illumina and IonTorrent platforms.
All Diatech products are developed under EN ISO 9001 and EN ISO 13485 and have been designed, developed and validated in accordance with the Directive 98/79/EC on in vitro diagnostic medical devices (CE-IVD).